PTPI (Petros Pharmaceuticals, Inc.) Enterprise Value-to-Revenue Coefficient

Petros Pharmaceuticals Inc (PTPI) - corporate logo

Petros Pharmaceuticals (PTPI) relies on a closed B2B distribution network for urological products, which guarantees market stability. This EV/Sales chart demonstrates valuation dynamics, where the value captures the metric level. The optimization of confidential prescription drug delivery reduces costs, while independence from global macroeconomic cycles transforms the company into a reliable defensive asset.

Petros Pharmaceuticals, Inc. - PTPI Enterprise Value-to-Revenue Ratio (period 07/04/2022 - 11/20/2026)

Financial and market metric breakdowns for Petros (PTPI)

- business market valuation indicators:
- cash and cash flow indicators:
Initial company analysis:Petros Pharmaceuticals
Original product of Petros Pharmaceuticals Inc

This multiple compares the total enterprise value with the volume of generated sales, excluding the impact of debt load to identify the real market value of assets. An analysis of the valuation of Petros Pharmaceuticals (PTPI) based on revenue excluding debt allows for the separation of the company's operational efficiency from financial fluctuations, confirming business resilience through the full localization of logistics and the protection of supply chains within the US.

Competitor analysis for Petros Pharmaceuticals

HLN: Enterprise Value-to-Revenue Ratio|Kenvue Corp (KVUE) - Enterprise Value-to-Revenue Ratio|Verona Pharma PLC - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Jyong Biotech Ltd|EV/Sales Multiple Ligand Corp|EV/Sales Multiple AMRX|Total Company Value-to-Revenue Ratio Perrigo Company plc|EV/Sales Multiple ALVO (Alvotech Biopharmaceuticals)|LQDA: Company Value to Revenue Ratio|Galapagos N.V. - EV/Sales Multiple|ANIP - EV/Sales Multiple|MNKD: EV/Sales Multiple|amphastar.com (AMPH) - EV/Sales Multiple|PCRX (Pacira Pharmaceuticals) - EV/Sales Multiple|Company Value to Revenue ARS Pharmaceuticals, Inc. (SPRY)|EV/Sales Multiple TBPH|AQST (Aquestive Therapeutics) - Business Value to Revenue|scPharmaceuticals, Inc. - Company Value to Revenue|Business Value to Revenue TECX|tonixpharma.com - EV/Sales Multiple|Business Value to Revenue SXTC (sxtchina.com)|Eupraxia Pharma (EPRX) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue BioHarvest|Company Value to Revenue EXOZ|Company Value to Revenue Oramed Pharmaceuticals (ORMP)|Company Value to Revenue ENTX (Entera Bio Corp)|MindWalk Holdings Inc. - Company Value to Revenue Ratio|EV/Sales Multiple ABVC (ABVC BioPharma Inc)|CPIX - Company Value to Revenue|Quantum BioPharma Corp - EV/Sales Multiple|FGEN (fibrogen.com) - Company Value to Revenue Ratio|TELO (Telomir Pharmaceuticals) - Company Value to Revenue|Rani Therapeutics Holdings - Business Value to Revenue|Company Value to Revenue SNYR|Enterprise Value-to-Revenue Multiple rallybio.com RLYB|EV/Sales Multiple LEXX|PULM (Pulmatrix, Inc.) - Business Value to Revenue|Pheton Holdings - Company Value to Revenue|EV/Sales Multiple Aptorum Group Limited APM|LYRA: Company Value to Revenue|IBO: Enterprise Value-to-Revenue Ratio|TNFA: EV/Sales Multiple|YCBD: Enterprise Value-to-Revenue Coefficient|Enterprise Value-to-Revenue Ratio PainReform Ltd|CYTO (altamiratherapeutics.com) - Enterprise Value-to-Revenue Coefficient|EV/Sales Multiple LIPO|OPTN - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio pieris.com PIRS|Business Value to Revenue PROC|QLI - Enterprise Value-to-Revenue Ratio|Business Value to Revenue SLRN (ACELYRIN)|TFF Pharmaceuticals, Inc (TFFP) - Enterprise Value-to-Revenue Ratio